175 related articles for article (PubMed ID: 22594690)
1. A selective, orally bioavailable 1,2,4-triazolo[1,5-a]pyridine-based inhibitor of Janus kinase 2 for use in anticancer therapy: discovery of CEP-33779.
Dugan BJ; Gingrich DE; Mesaros EF; Milkiewicz KL; Curry MA; Zulli AL; Dobrzanski P; Serdikoff C; Jan M; Angeles TS; Albom MS; Mason JL; Aimone LD; Meyer SL; Huang Z; Wells-Knecht KJ; Ator MA; Ruggeri BA; Dorsey BD
J Med Chem; 2012 Jun; 55(11):5243-54. PubMed ID: 22594690
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and evaluation of novel VEGFR2 kinase inhibitors: discovery of [1,2,4]triazolo[1,5-a]pyridine derivatives with slow dissociation kinetics.
Oguro Y; Cary DR; Miyamoto N; Tawada M; Iwata H; Miki H; Hori A; Imamura S
Bioorg Med Chem; 2013 Aug; 21(15):4714-29. PubMed ID: 23755884
[TBL] [Abstract][Full Text] [Related]
3. 2-Amino-[1,2,4]triazolo[1,5-a]pyridines as JAK2 inhibitors.
Siu M; Pastor R; Liu W; Barrett K; Berry M; Blair WS; Chang C; Chen JZ; Eigenbrot C; Ghilardi N; Gibbons P; He H; Hurley CA; Kenny JR; Cyrus Khojasteh S; Le H; Lee L; Lyssikatos JP; Magnuson S; Pulk R; Tsui V; Ultsch M; Xiao Y; Zhu BY; Sampath D
Bioorg Med Chem Lett; 2013 Sep; 23(17):5014-21. PubMed ID: 23870430
[TBL] [Abstract][Full Text] [Related]
4. Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.
Zak M; Mendonca R; Balazs M; Barrett K; Bergeron P; Blair WS; Chang C; Deshmukh G; Devoss J; Dragovich PS; Eigenbrot C; Ghilardi N; Gibbons P; Gradl S; Hamman C; Hanan EJ; Harstad E; Hewitt PR; Hurley CA; Jin T; Johnson A; Johnson T; Kenny JR; Koehler MF; Bir Kohli P; Kulagowski JJ; Labadie S; Liao J; Liimatta M; Lin Z; Lupardus PJ; Maxey RJ; Murray JM; Pulk R; Rodriguez M; Savage S; Shia S; Steffek M; Ubhayakar S; Ultsch M; van Abbema A; Ward SI; Xiao L; Xiao Y
J Med Chem; 2012 Jul; 55(13):6176-93. PubMed ID: 22698084
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
Dymock BW; See CS
Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
[TBL] [Abstract][Full Text] [Related]
6. Discovery of 1-amino-5H-pyrido[4,3-b]indol-4-carboxamide inhibitors of Janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders.
Lim J; Taoka B; Otte RD; Spencer K; Dinsmore CJ; Altman MD; Chan G; Rosenstein C; Sharma S; Su HP; Szewczak AA; Xu L; Yin H; Zugay-Murphy J; Marshall CG; Young JR
J Med Chem; 2011 Oct; 54(20):7334-49. PubMed ID: 21942426
[TBL] [Abstract][Full Text] [Related]
7. SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors.
Forsyth T; Kearney PC; Kim BG; Johnson HW; Aay N; Arcalas A; Brown DS; Chan V; Chen J; Du H; Epshteyn S; Galan AA; Huynh TP; Ibrahim MA; Kane B; Koltun ES; Mann G; Meyr LE; Lee MS; Lewis GL; Noguchi RT; Pack M; Ridgway BH; Shi X; Takeuchi CS; Zu P; Leahy JW; Nuss JM; Aoyama R; Engst S; Gendreau SB; Kassees R; Li J; Lin SH; Martini JF; Stout T; Tong P; Woolfrey J; Zhang W; Yu P
Bioorg Med Chem Lett; 2012 Dec; 22(24):7653-8. PubMed ID: 23127890
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitor.
Cee VJ; Schenkel LB; Hodous BL; Deak HL; Nguyen HN; Olivieri PR; Romero K; Bak A; Be X; Bellon S; Bush TL; Cheng AC; Chung G; Coats S; Eden PM; Hanestad K; Gallant PL; Gu Y; Huang X; Kendall RL; Lin MH; Morrison MJ; Patel VF; Radinsky R; Rose PE; Ross S; Sun JR; Tang J; Zhao H; Payton M; Geuns-Meyer SD
J Med Chem; 2010 Sep; 53(17):6368-77. PubMed ID: 20684549
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 1-methyl-1H-imidazole derivatives as potent Jak2 inhibitors.
Su Q; Ioannidis S; Chuaqui C; Almeida L; Alimzhanov M; Bebernitz G; Bell K; Block M; Howard T; Huang S; Huszar D; Read JA; Rivard Costa C; Shi J; Su M; Ye M; Zinda M
J Med Chem; 2014 Jan; 57(1):144-58. PubMed ID: 24359159
[TBL] [Abstract][Full Text] [Related]
10. Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.
Zak M; Hurley CA; Ward SI; Bergeron P; Barrett K; Balazs M; Blair WS; Bull R; Chakravarty P; Chang C; Crackett P; Deshmukh G; DeVoss J; Dragovich PS; Eigenbrot C; Ellwood C; Gaines S; Ghilardi N; Gibbons P; Gradl S; Gribling P; Hamman C; Harstad E; Hewitt P; Johnson A; Johnson T; Kenny JR; Koehler MF; Bir Kohli P; Labadie S; Lee WP; Liao J; Liimatta M; Mendonca R; Narukulla R; Pulk R; Reeve A; Savage S; Shia S; Steffek M; Ubhayakar S; van Abbema A; Aliagas I; Avitabile-Woo B; Xiao Y; Yang J; Kulagowski JJ
J Med Chem; 2013 Jun; 56(11):4764-85. PubMed ID: 23659214
[TBL] [Abstract][Full Text] [Related]
11. Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors.
Brasca MG; Nesi M; Avanzi N; Ballinari D; Bandiera T; Bertrand J; Bindi S; Canevari G; Carenzi D; Casero D; Ceriani L; Ciomei M; Cirla A; Colombo M; Cribioli S; Cristiani C; Della Vedova F; Fachin G; Fasolini M; Felder ER; Galvani A; Isacchi A; Mirizzi D; Motto I; Panzeri A; Pesenti E; Vianello P; Gnocchi P; Donati D
Bioorg Med Chem; 2014 Sep; 22(17):4998-5012. PubMed ID: 25009002
[TBL] [Abstract][Full Text] [Related]
12. Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2.
Lu LD; Stump KL; Wallace NH; Dobrzanski P; Serdikoff C; Gingrich DE; Dugan BJ; Angeles TS; Albom MS; Mason JL; Ator MA; Dorsey BD; Ruggeri BA; Seavey MM
J Immunol; 2011 Oct; 187(7):3840-53. PubMed ID: 21880982
[TBL] [Abstract][Full Text] [Related]
13. Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
Zhu GD; Gandhi VB; Gong J; Thomas S; Woods KW; Song X; Li T; Diebold RB; Luo Y; Liu X; Guan R; Klinghofer V; Johnson EF; Bouska J; Olson A; Marsh KC; Stoll VS; Mamo M; Polakowski J; Campbell TJ; Martin RL; Gintant GA; Penning TD; Li Q; Rosenberg SH; Giranda VL
J Med Chem; 2007 Jun; 50(13):2990-3003. PubMed ID: 17523610
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity.
Wittman M; Carboni J; Attar R; Balasubramanian B; Balimane P; Brassil P; Beaulieu F; Chang C; Clarke W; Dell J; Eummer J; Frennesson D; Gottardis M; Greer A; Hansel S; Hurlburt W; Jacobson B; Krishnananthan S; Lee FY; Li A; Lin TA; Liu P; Ouellet C; Sang X; Saulnier MG; Stoffan K; Sun Y; Velaparthi U; Wong H; Yang Z; Zimmermann K; Zoeckler M; Vyas D
J Med Chem; 2005 Sep; 48(18):5639-43. PubMed ID: 16134929
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and anticancer activity evaluation of a series of [1,2,4]triazolo[1,5-a]pyridinylpyridines in vitro and in vivo.
Wang XM; Xu J; Li YP; Li H; Jiang CS; Yang GD; Lu SM; Zhang SQ
Eur J Med Chem; 2013 Sep; 67():243-51. PubMed ID: 23871904
[TBL] [Abstract][Full Text] [Related]
16. Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma.
William AD; Lee AC; Blanchard S; Poulsen A; Teo EL; Nagaraj H; Tan E; Chen D; Williams M; Sun ET; Goh KC; Ong WC; Goh SK; Hart S; Jayaraman R; Pasha MK; Ethirajulu K; Wood JM; Dymock BW
J Med Chem; 2011 Jul; 54(13):4638-58. PubMed ID: 21604762
[TBL] [Abstract][Full Text] [Related]
17. Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors.
Kulagowski JJ; Blair W; Bull RJ; Chang C; Deshmukh G; Dyke HJ; Eigenbrot C; Ghilardi N; Gibbons P; Harrison TK; Hewitt PR; Liimatta M; Hurley CA; Johnson A; Johnson T; Kenny JR; Bir Kohli P; Maxey RJ; Mendonca R; Mortara K; Murray J; Narukulla R; Shia S; Steffek M; Ubhayakar S; Ultsch M; van Abbema A; Ward SI; Waszkowycz B; Zak M
J Med Chem; 2012 Jun; 55(12):5901-21. PubMed ID: 22591402
[TBL] [Abstract][Full Text] [Related]
18. Discovery of potent and highly selective thienopyridine Janus kinase 2 inhibitors.
Schenkel LB; Huang X; Cheng A; Deak HL; Doherty E; Emkey R; Gu Y; Gunaydin H; Kim JL; Lee J; Loberg R; Olivieri P; Pistillo J; Tang J; Wan Q; Wang HL; Wang SW; Wells MC; Wu B; Yu V; Liu L; Geuns-Meyer S
J Med Chem; 2011 Dec; 54(24):8440-50. PubMed ID: 22087750
[TBL] [Abstract][Full Text] [Related]
19. Discovery and optimization of a series of 3-(3-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: orally bioavailable, selective, and potent ATP-independent Akt inhibitors.
Ashwell MA; Lapierre JM; Brassard C; Bresciano K; Bull C; Cornell-Kennon S; Eathiraj S; France DS; Hall T; Hill J; Kelleher E; Khanapurkar S; Kizer D; Koerner S; Link J; Liu Y; Makhija S; Moussa M; Namdev N; Nguyen K; Nicewonger R; Palma R; Szwaya J; Tandon M; Uppalapati U; Vensel D; Volak LP; Volckova E; Westlund N; Wu H; Yang RY; Chan TC
J Med Chem; 2012 Jun; 55(11):5291-310. PubMed ID: 22533986
[TBL] [Abstract][Full Text] [Related]
20. Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease.
Sunose M; Bell K; Ellard K; Bergamini G; Neubauer G; Werner T; Ramsden N
Bioorg Med Chem Lett; 2012 Jul; 22(14):4613-8. PubMed ID: 22726925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
